Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02033369 · ClinicalTrials.gov registry record · Phase 4
Imaging Dopamine Release in Depression
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT02033369 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 52 participants.
The verdict
NCT02033369, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study aims to determine whether ventral striatal dopamine release is a mechanism of reward motivation in major depression, whether dopamine release is low in depression, and whether DA release and reward motivation predict response to dopamine-targeted treatment with pramipexole.
Interventions
- DRUG Pramipexole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02033369
The ClinicalTrials.gov registry entry for NCT02033369 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pramipexole is the first listed.
NCT02033369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02033369 about?
NCT02033369 is a clinical study titled "Imaging Dopamine Release in Depression". This study aims to determine whether ventral striatal dopamine release is a mechanism of reward motivation in major depression, whether dopamine release is low in depression, and whether DA release and reward motivation predict response to dopamine-targeted treatment with pramipexole.
What is the current status of trial NCT02033369?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2014-02. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02033369?
The interventions under investigation include: Pramipexole (DRUG).
Who is sponsoring clinical trial NCT02033369?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.